​

Funding Round

Series B - Odyssey Therapeutics

Series B - Odyssey Therapeutics

Investment Firm

Overview

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

Announced Date

Oct 13, 2022

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

General Catalyst

General Catalyst

General Catalyst is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

15

Investor Name
Participant InvestorForesite Capital
Participant InvestorT. Rowe Price
Participant InvestorGreatPoint Ventures
Participant InvestorGeneral Catalyst
Participant InvestorFidelity

Round Details and Background

Odyssey Therapeutics raised $168000000 on 2022-10-13 in Series B

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 07, 2021
Series A - Odyssey Therapeutics
8-218.0M
Oct 13, 2022
Series B - Odyssey Therapeutics
16-168.0M
Dec 05, 2023
Series C - Odyssey Therapeutics
21-101.0M

Recent Activity

There is no recent news or activity for this profile.